Paraoxonase-1 status in patients with hereditary hemochromatosis

Journal of Lipid Research

Volumn 54, Issue 5, 2013, Pages 1484-1492

  Martinelli, Nicola ^a   García Heredia, Anabel ^b   Roca, Helena ^b   Aranda, Núria ^c   Arija, Victoria ^c   Mackness, Bharti ^b   Mackness, Michael ^b   Busti, Fabiana ^a   Aragonés, Gerard ^b   Pedro Botet, Juan ^d   Pedica, Federica ^e   Cataldo, Ivana ^e   Marsillach, Judit ^f   Joven, Jorge ^b   Girelli, Domenico ^a   Camps, Jordi ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^d UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antioxidants; Inflammation; Iron metabolism; Oxidative stress

Indexed keywords

8 ISOPROSTANE; ARYLDIALKYLPHOSPHATASE 1; FERRITIN; LIPID PEROXIDE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME POLYMORPHISM; FATTY ACID BLOOD LEVEL; FEMALE; GENETIC VARIABILITY; HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCHEMISTRY; LIVER BIOPSY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PARAOXONASE 1 GENE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; BIOPSY; DINOPROST; FEMALE; FERRITINS; GENE EXPRESSION REGULATION; HEMOCHROMATOSIS; HUMANS; IRON; LIPID PEROXIDATION; LIVER; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 84876815322     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P028977     Document Type: Article

References (52)

1. Pietrangelo, A. 2010. Hereditary hemochromatosis: Pathogenesis, diagnosis, and treatment. Gastroenterology. 139 : 393-408.
2. Ramm, G. A., and R. G. Ruddell. 2010. Iron homeostasis, hepatocellular injury, and fi brogenesis in hemochromatosis: The role of inflammation in a noninflammatory liver disease. Semin. Liver Dis. 30 : 271-287.
3. Kom, G. D., E. Schwedhelm, P. Nielsen, and R. H. Böger. 2006. Increased urinary excretion of 8-iso-prostaglandin F 2 α in patients with HFE-related hemochromatosis: A case-control study. Free Radic. Biol. Med. 40 : 1194-1200.
4. Broedbaek, K., H. E. Poulsen, A. Weimann, G. D. Kom, E. Schwedhelm, P. Nielsen, and H. Böger. 2009. Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis. Free Radic. Biol. Med. 47 : 1230-1233.
5. Singh, B., S. Arora, P. Agrawal, and S. K. Gupta. 2011. Hepcidin: A novel peptide hormone regulation iron metabolism. Clin. Chim. Acta. 412 : 823-830.
6. Harel, M., A. Aharoni, L. Gaidukov, B. Brumshtein, O. Khersonsky, R. Meged, H. Dvir, R. B. Ravelli, A. McCarthy, L. Toker, et al. 2004. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11 : 412-419.
7. Khersonsky, O., and D. S. Tawfik. 2005. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 44 : 6371-6382.
8. Draganov, D. I., J. F. Teiber, A. Speelman, Y. Osawa, R. Sunahara, and B. N. La Du. 2005. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46 : 1239-1247.
9. Camps, J., J. Marsillach, and J. Joven. 2009. The paraoxonases: Role in human diseases and methodological diffi culties in measurement. Crit. Rev. Clin. Lab. Sci. 46 : 83-106.
10. Rodríguez-Sanabria, F., A. Rull, R. Beltrán-Debón, G. Aragonès, J. Camps, B. Mackness, M. Mackness, and J. Joven. 2010. Tissue distribution and expression of paraoxonases and chemokines in mouse: The ubiquitous and joint localisation suggest a systemic and coordinated role. J. Mol. Histol. 41 : 379-386.
11. Marsillach, J., B. Mackness, M. Mackness, F. Riu, R. Beltrán, J. Joven, and J. Camps. 2008. Immunochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic. Biol. Med. 45 : 146-157.
12. Deakin, S. P., S. Bioletto, M. L. Bochaton-Piallat, and R. W. James. 2011. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic. Biol. Med. 50 : 102-109.
13. Ferré, N., J. Marsillach, J. Camps, B. Mackness, M. Mackness, F. Riu, B. Coll, M. Tous, and J. Joven. 2006. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J. Hepatol. 45 : 51-59.
14. Marsillach, J., N. Ferré, M. C. Vila, A. Lligoña, B. Mackness, M. Mackness, R. Deulofeu, R. Solá, A. Parés, J. Pedro-Botet, et al. 2007. Serum paraoxonase-1 in chronic alcoholics: Relationship with liver disease. Clin. Biochem. 40 : 645-650.
15. Marsillach, J., G. Aragonès, B. Mackness, M. Mackness, A. Rull, R. Beltrán-Debón, J. Pedro-Botet, C. Alonso-Villaverde, J. Joven, and J. Camps. 2010. Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids Health Dis. 9 : 46.
16. Zhang, C., W. Peng, X. Jiang, B. Chen, J. Zhu, Y. Zang, J. Zhang, T. Zhu, and J. Qin. 2008. Transgene expression of human PON1 Q in mice protects the liver against CCl 4 induced injury. J. Gene Med. 10 : 94-100.
17. Ustundag, B., I. H. Bahcecioglu, K. Sahin, S. Duzgun, S. Koca, F. Gulcu, and I. H. Ozercan. 2007. Protective effect of soy isofl avones and activity levels of plasma paraoxonase and arylesterase in the experimental non-alcoholic steatohepatitis model. Dig. Dis. Sci. 52 : 2006-2014.
18. Holland, N., C. Furlong, M. Bastaki, R. Richter, A. Bradman, K. Huen, K. Beckman, and B. Eskenazi. 2006. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. Environ. Health Perspect. 114 : 985-991.
19. Gaidukov, L., and D. Tawfik. 2007. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J. Lipid Res. 48 : 1637-1646.
20. Aranda, N., F. E. Viteri, J. Fernández-Ballart, M. Murphy, and V. Arija. 2007. Frequency of the hemochromatosis gene (HFE) 282C → Y, 63H → D, and 65S → C mutations in a general Mediterranean population from Tarragona, Spain. Ann. Hematol. 86 : 17-21.
21. Aranda, N., F. E. Viteri, C. Montserrat, and V. Arija. 2010. Effects of C282Y, H63D, and S65C HFE mutations, diet, and life-style factors on iron status in a general Mediterranean population from Tarragona, Spain. Ann. Hematol. 89 : 767-773.
22. Ferré, N., J. Camps, E. Prats, E. Vilella, A. Paul, L. Figuera, and J. Joven. 2002. Serum paraoxonase activity: A new additional test for the improved evaluation of chronic liver damage. Clin. Chem. 48 : 261-268.
23. Eckerson, H.W, C. M. Wyte, and B. N. La Du. The human serum paraoxonase/arylesterase polymorphism. 1983. Am. J. Hum. Genet. 35 : 1126-1138.
24. Marsillach, J., G. Aragonès, R. Beltrán, J. Caballeria, J. Pedro-Botet, C. Morcillo-Suárez, A. Navarro, J. Joven, and J. Camps. 2009. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin. Biochem. 42 : 91-98.
25. Martinelli, N., D. Girelli, O. Olivieri, P. Guarini, A. Bassi, E. Trabetti, S. Friso, F. Pizzolo, C. Bozzini, I. Tenuti, et al. 2009. Novel serum paraoxonase activity assays are associated with coronary artery disease. Clin. Chem. Lab. Med. 47 : 432-440.
26. Martinelli, N., R. Micaglio, L. Consoli, P. Guarini, E. Grison, F. Pizzolo, S. Friso, E. Trabetti, P. F. Pignatti, R. Corrocher, et al. 2012. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease. Exp. Diabetes Res. 2012 : 231502.
27. Rull, A., J. Camps, C. Alonso-Villaverde, and J. Joven. Insulin resistance, inflammation, and obesity: Role of monocyte chemoattractant protein-1 (or CCL2) in the regulation of metabolism. 2010. Mediators Infl amm. 2010: Volume ID 326580.
28. Thellin, O., W. Zorzi, B. Lakaye, B. De Borman, B. Coumans, G. Hennen, T. Grisar, A. Igout, and E. Heinen. 1999. Housekeeping genes as internal standards: Use and limits. J. Biotechnol. 75 : 291-295.
29. Stevens, R. G., J. E. Morris, G. A. Cordis, L. E. Anderson, D. W. Rosenberg, and L. B. Sasser. 2003. Oxidative damage in colon and mammary tissue of the HFE-knockout mouse. Free Radic. Biol. Med. 34 : 1212-1216.
30. Camps, J., J. Marsillach, A. Rull, C. Alonso-Villaverde, and J. Joven. 2010. Interrelationships between paraoxonase-1 and monocyte chemoattractant protein-1 in the regulation of hepatic inflammation. Adv. Exp. Med. Biol. 660 : 5-18.
31. Marsillach, J., J. Camps, N. Ferré, R. Beltran, A. Rull, B. Mackness, M. Mackness, and J. Joven. 2009. Paraoxonase-1 is related to inflammation, fibrosis and PPAR α in experimental liver disease. BMC Gastroenterol. 9 : 3.
32. James, R. W., and S. P. Deakin. 2004. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic. Biol. Med. 37 : 1986-1994.
33. Marchesini, G., M. Brizi, G. Bianchi, S. Tomassetti, E. Bugianesi, M. Lenzi, A. J. McCullough, S. Natale, G. Forlani, and N. Melchionda. 2001. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes. 50 : 1844-1850.
34. Van Lerberghe, S., M. P. Hermans, K. Dahan, and M. Buysschaert. 2002. Clinical expression and insulin sensitivity in type 2 diabetic patients with heterozygous mutations for haemochromatosis. Diabetes Metab. 28 : 33-38.
35. Jehn, M., J. M. Clark, and E. Guallar. 2004. Serum ferritin and risk of the metabolic syndrome in US adults. Diabetes Care. 27 : 2422-2428.
36. Aviram, M., M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, C. L. Bisgaier, R. S. Newton, and B. La Du. 1999. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26 : 892-904.
37. Barton, J. C., J. C. Barton, R. T. Acton, S. Chan, and P. C. Adams. 2012. Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin above 1000 micrograms/liter at diagnosis. Clin. Gastroenterol. Hepatol. 10 : 412-416.
38. Besler, C., K. Heinrich, L. Rohrer, C. Doerries, M. Riwanto, D. M. Shih, A. Chroni, K. Yonekawa, S. Stein, N. Schaefer, et al. 2011. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest. 121 : 2693-2708.
39. Van Lenten, B. J., A. C. Wagner, M. Navab, and A. M. Fogelman. 2001. Oxidized phospholipids induce changes in hepatic paraoxonase and apoJ but not monocyte chemoattractatn protein-1 via interleukin-6. J. Biol. Chem. 276 : 1923-1929.
40. Kumon, Y., Y. Nakauchi, T. Suehiro, T. Shiinoki, N. Tanimoto, M. Inoue, T. Nakamura, K. Hashimoto, and J. D. Sipe. 2002. Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells. Amyloid. 9 : 160-164.
41. Han, C. Y., T. Chiba, J. S. Campbell, N. Fausto, M. Chaisson, G. Orasanu, J. Plutzky, and A. Chait. 2006. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler. Thromb. Vasc. Biol. 26 : 1806-1813.
42. Kang, H. T., J. A. Linton, and J. Y. Shim. 2012. Serum ferritin level is associated with the prevalence of metabolic syndrome in Korean adults: The 2007-2008 Korean National Health and Nutrition Examination Survey. Clin. Chim. Acta. 413 : 636-641.
43. Sentí, M., M. Tomás, M. Fitó, T. Weinbrenner, M. I. Covas, J. Sala, R. Masiá, and J. Marrugat. 2003. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 88 : 5422-5426.
44. Mackness, B., M. I. Mackness, S. Arrol, W. Turkie, and P. N. Durrington. 1998. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 423 : 57-60.
45. Ferré, N., J. Marsillach, J. Camps, A. Rull, B. Coll, M. Tous, and J. Joven. 2005. Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. Clin. Chim. Acta. 361 : 206-210.
46. Parra, S., J. Marsillach, G. Aragonés, R. Beltrán, M. Montero, B. Coll, B. Mackness, M. Mackness, C. Alonso-Villaverde, J. Joven, et al. 2010. Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIVinfected patients. J. Infect. Dis. 201 : 627-634.
47. Wang, M., X. Lang, L. Zou, S. Huang, and Z. Xu. 2011. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: A meta-analysis based on 88 case-control studies. Atherosclerosis. 214 : 377-385.
48. Fang, D. H., C. H. Fan, Q. Ji, B. X. Qi, J. Li, and L. Wang. 2012. Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: Evidence from 25 published studies. Mol. Biol. Rep. 39 : 6801-6809.
49. Weiss, G. 2010. Genetic mechanisms and modifying factors in hereditary hemochromatosis. Nat. Rev. Gastroenterol. Hepatol. 7 : 50-58.
50. Gan, E. K., L. W. Powell, and J. K. Olynyk. 2011. Natural history and management of HFE-hemochromatosis. Semin. Liver Dis. 31 : 293-301.
51. Allen, K. J., L. C. Gurrin, C. C. Constantine, N. J. Osborne, M. B. Delatycki, A. J. Nicoll, C. E. McLaren, M. Bahlo, A. E. Nisselle, C. D. Vulpe, et al. 2008. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 358 : 221-230.
52. Wood, M. J., L. W. Powell, and G. A. Ramm. 2008. Environmental and genetic modifi ers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood. 111 : 4456-4462.